468 studies found for:    glioma | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas
Conditions: Glial Cell Tumors;   Malignant Gliomas;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Gliomatosis Cerebri;   Gliosarcoma;   Brainstem Glioma
Interventions: Drug: Valproic acid;   Drug: Bevacizumab;   Radiation: Radiation therapy
22 Recruiting Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor
Conditions: Glioma;   Glioblastoma;   Glioblastoma Multiforme;   GBM;   Brain Cancer
Intervention: Drug: VAL-083
23 Unknown  Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
Condition: Recurrent Malignant Glioma
Intervention: Drug: Bevacizumab / Irinotecan
24 Unknown  Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
Condition: Glioma
Intervention: Biological: GM-K562 Vaccination
25 Recruiting Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Condition: Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Interventions: Drug: CTO;   Drug: CTO and Temodar®;   Drug: CTO, Temodar®, Radiation therapy
26 Recruiting 68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
Condition: Glioma
Intervention: Drug: 68Ga-BNOTA-PRGD2
27 Recruiting Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
Condition: Malignant Glioma (WHO Grade III or IV)
Interventions: Drug: CTO and lomustine;   Drug: CTO alone;   Drug: Lomustine alone
28 Recruiting Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
Conditions: Diffuse Intrinsic Pontine Glioma;   Glioblastoma Multiforme;   Adult Glioblastoma
Interventions: Biological: Tumor Lysate Vaccine;   Drug: Imiquimod;   Radiation: Radiation therapy
29 Recruiting 5-ALA in Recurrent Glioma
Condition: Recurrent Glioma
Intervention: Drug: 5-ala
30 Recruiting Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
Condition: Glioma
Intervention: Drug: nilotinib
31 Recruiting Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Condition: Malignant Glioma (WHO Grade III or IV)
Interventions: Drug: CTO and Bevacizumab;   Drug: CTO alone
32 Recruiting Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
Conditions: Brain Cancer;   MALIGNANT GLIOMA;   Glioblastoma;   Anaplastic Astrocytoma (AA);   Anaplastic Oligodendroglioma (AO);   Anaplastic Oligo-astrocytoma (AOA);   Anaplastic Mixed Gliomas;   Malignant Glioma NOS
Intervention: Other: Bevacizumab & Stereotactic Radiotherapy
33 Recruiting ANG1005 in Patients With Recurrent High-Grade Glioma
Conditions: Glioma;   Glioblastoma;   Brain Tumor, Recurrent
Interventions: Drug: ANG1005;   Drug: Bevacizumab
34 Recruiting Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma
Condition: Grade IV Malignant Glioma
Intervention: Biological: ALD-451
35 Unknown  Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
Condition: Malignant Glioma
Intervention: Biological: Biological: DC activated CIK combined with DC
36 Recruiting Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Conditions: Adult Diffuse Astrocytoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor;   Adult Oligoastrocytoma
Interventions: Biological: tumor lysate-pulsed autologous dendritic cell vaccine;   Other: laboratory biomarker analysis
37 Recruiting Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas
Condition: Pediatric High Risk Gliomas
Intervention: Drug: Combination of two marketed drugs (irinotecan and cisplatin)
38 Recruiting Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age
Conditions: Glioblastoma Multiforme;   Fibrillary Astrocytoma of Brain;   Glioma of Brainstem;   Anaplastic Astrocytoma;   Pilomyxoid Astrocytoma;   Mixed Oligodendroglioma-Astrocytoma;   Brain Stem Glioma;   Diffuse Intrinsic Pontine Glioma;   High Grade Glioma
Intervention: Drug: SIACI of Erbitux (200 m/m2) and Bevacizumab(15 mg/kg)
39 Recruiting Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma
Conditions: Low-grade Glioma;   Astrocytoma;   Oligodendroglioma;   Mixed Oligoastrocytoma
Intervention: Drug: RAD001
40 Recruiting Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Conditions: Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Mixed Glioma;   Childhood Pilocytic Astrocytoma;   Neurofibromatosis Type 1;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis;   Other: pharmacological study

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years